On December 24, Gelonghui reported that HENLIUS (02696.HK) announced that recently, an international multicenter phase III clinical trial entitled "ELAINE-3" comparing HLX78 (lasofoxifene) in combination with Abemaciclib and Fulvestrant for the treatment of pre/postmenopausal women and men with locally advanced or metastatic breast cancer who have previously received aromatase inhibitors (AI) in combination with Palbociclib or Ribociclib (as the first hormone treatment regimen for metastatic disease), estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), and carrying estrogen receptor 1 (ESR1) mutations has completed the first patient dosing in mainland China. Currently, partner Sermonix Pharmaceuticals, Inc. is conducting the ELAINE-3 study globally, which has completed the first patient dosing worldwide in January 2024 and is also enrolling patients in the USA, Europe, Canada, and other regions.